Drugs commonly associated with weight change: A systematic review and meta-analysis

Journal of Clinical Endocrinology and Metabolism

Volumn 100, Issue 2, 2015, Pages 363-370

  Domecq, Juan Pablo ^a,b   Prutsky, Gabriela ^a,b   Leppin, Aaron ^a   Sonbol, M Bassam ^a   Altayar, Osama ^a   Undavalli, Chaitanya ^a   Wang, Zhen ^a   Elraiyah, Tarig ^a   Brito, Juan Pablo ^a   Mauck, Karen F ^a   Lababidi, Mohammed H ^a   Prokop, Larry J ^a   Asi, Noor ^a   Wei, Justin ^a   Fidahussein, Salman ^a   Montori, Victor M ^a,b   Murad, Mohammad Hassan ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSIDAD PERUANA CAYETANO HEREDIA   (Peru)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; AMFEBUTAMONE; AMITRIPTYLINE; ARIPIPRAZOLE; CARBAMAZEPINE; EXENDIN 4; FLUOXETINE; GABAPENTIN; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; LIRAGLUTIDE; METFORMIN; MIGLITOL; MIRTAZAPINE; NATEGLINIDE; OLANZAPINE; PIOGLITAZONE; PRAMLINTIDE; QUETIAPINE; RISPERIDONE; SITAGLIPTIN; TOPIRAMATE; VALPROATE SEMISODIUM; ZIPRASIDONE; ZONISAMIDE; ANTIDIABETIC AGENT; NEUROLEPTIC AGENT;

ADVERSE OUTCOME; ARTICLE; DRUG CHOICE; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; HUMAN; MEDICAL DECISION MAKING; META ANALYSIS; PRESCRIPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; WEIGHT CHANGE; WEIGHT GAIN; WEIGHT REDUCTION; BODY WEIGHT; DRUG EFFECTS;

ANTIPSYCHOTIC AGENTS; BODY WEIGHT; HUMANS; HYPOGLYCEMIC AGENTS; WEIGHT GAIN; WEIGHT LOSS;

EID: 84922486127     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2014-3421     Document Type: Article

References (47)

1. Barness LA, Opitz JM, Gilbert-Barness E. Obesity: genetic, molecular, and environmental aspects. Am J Med Genet A. 2007; 143A: 3016-3034.
2. World Health Organization. Fact Sheet: Obesity and Overweight. Geneva, Switzerland: World Health Organization; 2011.
3. Vasan RS, Pencina MJ, Cobain M, Freiberg MS, D'Agostino RB. Estimated risks for developing obesity in the Framingham Heart Study. Ann Intern Med. 2005; 143: 473-480.
4. Flegal KM, Graubard BI, Williamson DF, Gail MH. Cause-specific excess deaths associated with underweight, overweight, and obesity. JAMA. 2007; 298: 2028-2037.
5. Prospective Studies Collaboration; Whitlock G, Lewington S, Sherliker P, et al. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet. 2009; 373: 1083-1096.
6. Preston SH, Stokes A. Contribution of obesity to international differences in life expectancy. Am J Public Health. 2011; 101: 2137-2143.
7. Perk J, De Backer G, Gohlke H, et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J. 2012; 33: 1635-1701.
8. Domecq JP, Prutsky G, Wang Z, et al. Drugs commonly associated with weight change: umbrella systematic review and meta-analysis (Protocol). Syst Rev. 2012; 1: 44.
9. Smith V, Devane D, Begley CM, Clarke M. Methodology in conducting a systematic review of systematic reviews of healthcare interventions. BMC Med Res Methodol. 2011; 11: 15.
10. Zhou YH, Ma XQ, Wu C, et al. Effect of anti-obesity drug on cardiovascular risk factors: a systematic review and meta-analysis of randomized controlled trials. PLoS One. 2012; 7: e39062.
11. Smith SM, Meyer M, Trinkley KE. Phentermine/topiramate for the treatment of obesity. Ann Pharmacother. 2013; 47: 340-349.
12. Dombrowski SU, Knittle K, Avenell A, Araújo-Soares V, Sniehotta FF. Long term maintenance of weight loss with non-surgical interventions in obese adults: systematic review and meta-analyses of randomised controlled trials. BMJ. 2014; 348: g2646.
13. Johansson K, Neovius M, Hemmingsson E. Effects of anti-obesity drugs, diet, and exercise on weight-loss maintenance after a very-low-calorie diet or low-calorie diet: a systematic review and metaanalysis of randomized controlled trials. Am J Clin Nutr. 2014; 99: 14-23.
14. Higgins JP, Green S. Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration. Version 5.1.0. Updated March 2011. Hoboken, NJ: Wiley; 2011.
15. Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta-analyses can provide accurate results. J Clin Epidemiol. 2006; 59: 7-10.
16. Swiglo BA, Murad MH, Schünemann HJ, et al. A case for clarity, consistency, and helpfulness: state-of-the-art clinical practice guide-lines in endocrinology using the grading of recommendations, assessment, development, and evaluation system. J Clin Endocrinol Metab. 2008; 93: 666-673.
17. Stevens J, Truesdale KP, McClain JE, Cai J. The definition of weight maintenance. Int J Obes (Lond). 2006; 30: 391-399.
18. Montori VM, Guyatt GH. Intention-to-treat principle. CMAJ. 2001; 165: 1339-1341.
19. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986; 7: 177-188.
20. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21: 1539-1558.
21. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994; 50: 1088-1101.
22. Lau J, Ioannidis JP, Terrin N, Schmid CH, Olkin I. The case of the misleading funnel plot. BMJ. 2006; 333: 597-600.
23. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009; 62: e1-34.
24. Da Silva JA, Jacobs JW, Kirwan JR, et al. Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Ann Rheum Dis. 2006; 65: 285-293.
25. Landewé RB, Boers M, Verhoeven AC, et al. COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum. 2002; 46: 347-356.
26. Robinson LE, Holt TA, Rees K, Randeva HS, O'Hare JP. Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis. BMJ Open. 2013; 3(1) pii: e001986.
27. Craddy P, Palin HJ, Johnson KI. Comparative effectiveness of dipeptidylpeptidase-4 inhibitors in type 2 diabetes: a systematic review and mixed treatment comparison. Diabetes Ther. 2014; 5: 1-41.
28. Klemp M, Tvete IF, Skomedal T, Gaasemyr J, Natvig B, Aursnes I. A review and Bayesian meta-analysis of clinical efficacy and adverse effects of 4 atypical neuroleptic drugs compared with haloperidol and placebo. J Clin Psychopharmacol. 2011; 31: 698-704.
29. Gartlehner G, Hansen RA, Morgan LC, et al. Second-Generation Antidepressants in the Pharmacologic Treatment of Adult Depression: An Update of the 2007 Comparative Effectiveness Review. Rockville, MD: Agency for Healthcare Research and Quality; 2011.
30. Wang T, Gou Z, Wang F, Ma M, Zhai SD. Comparison of GLP-1 analogues versus sitagliptin in the management of type 2 diabetes: systematic review and meta-analysis of head-to-head studies. PLoS One. 2014; 9: e103798.
31. Rynn M, Russell J, Erickson J, et al. Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial. Depress Anxiety. 2008; 25: 182-189.
32. Montgomery SA, Tobias K, Zornberg GL, Kasper S, Pande AC. Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine. J Clin Psychiatry. 2006; 67: 771-782.
33. Nemeroff CB, Thase ME. A double-blind, placebo-controlled comparison of venlafaxine and fluoxetine treatment in depressed outpatients. J Psychiatr Res. 2007; 41: 351-359.
34. Moscovitch A, Blashko CA, Eagles JM, et al. A placebo-controlled study of sertraline in the treatment of outpatients with seasonal affective disorder. Psychopharmacology (Berl). 2004; 171: 390-397.
35. Wise TN, Perahia DG, Pangallo BA, Losin WG, Wiltse CG. Effects of the antidepressant duloxetine on body weight: analyses of 10 clinical studies. Prim Care Companion J Clin Psychiatry. 2006; 8: 269-278.
36. Dungan KM, Povedano ST, Forst T, et al. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. Lancet. 2014; 384(9951): 1349-1357.
37. Benkhadra K, Wang Z, Murad MH. Network meta-analysis: introduction and an example that compares devices for PFO closure. Eur Heart J. 2014; pii: ehu343.
38. Danielsen KK, Svendsen M, Maehlum S, Sundgot-Borgen J. Changes in body composition, cardiovascular disease risk factors, and eating behavior after an intensive lifestyle intervention with high volume of physical activity in severely obese subjects: a prospective clinical controlled trial. J Obes. 2013; 2013: 325464.
39. Montori VM, Gandhi GY, Guyatt GH. Patient-important outcomes in diabetes-time for consensus. Lancet. 2007; 370: 1104-1106.
40. Björkhem-Bergman L, Asplund AB, Lindh JD. Metformin for weight reduction in non-diabetic patients on antipsychotic drugs: a systematic review and meta-analysis. J Psychopharmacol. 2011; 25: 299-305.
41. Das C, Mendez G, Jagasia S, Labbate LA. Second-generation anti-psychotic use in schizophrenia and associated weight gain: a critical review and meta-analysis of behavioral and pharmacologic treatments. Ann Clin Psychiatry. 2012; 24: 225-239.
42. Ehret M, Goethe J, Lanosa M, Coleman CI. The effect of metformin on anthropometrics and insulin resistancein patients receiving atypical antipsychotic agents: a meta-analysis. J Clin Psychiatry. 2010; 71: 1286-1292.
43. Fiedorowicz JG, Miller DD, Bishop JR, Calarge CA, Ellingrod VL, Haynes WG. Systematic review and meta-analysis of pharmacological interventions for weight gain from antipsychotics and mood stabilizers. Curr Psychiatry Rev. 2012; 8: 25-36.
44. Bartlett C, Doyal L, Ebrahim S, et al. The causes and effects of socio-demographic exclusions from clinical trials. Health Technol Assess. 2005; 9: iii-iv, ix-x, 1-152.
45. Sabanayagam C, Teo BW, Tai ES, Jafar TH, Wong TY. Ethnic differences in the association between blood pressure components and chronic kidney disease in middle aged and older Asian adults. BMC Nephrol. 2013; 14: 86.
46. Sabanayagam C, Teo BW, Tai ES, Jafar TH, Wong TY. Ethnic variation in the impact of metabolic syndrome components and chronic kidney disease. Maturitas. 2013; 74: 369-374.
47. Lanting LC, Joung IM, Mackenbach JP, Lamberts SW, Bootsma AH. Ethnic differences in mortality, end-stage complications, and quality of care among diabetic patients: a review. Diabetes Care. 2005; 28: 2280-2288.